|
90
|
263
|
4rfyA |
Crystal structure of btk kinase domain complexed with 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-3,4-dihydroisoquinolin-1-one |
|
103
|
349
|
4qp1A |
Crystal structure of erk2 in complex with n-cyclohexyl-9h-purin-6-amine |
|
92
|
348
|
4r8qA |
Structure and substrate recruitment of the human spindle checkpoint kinase bub1 |
|
81
|
284
|
4rrvA |
Crystal structure of pdk1 in complex with atp and piftide |
|
102
|
347
|
4qnyA |
Crystal structure of mapk from leishmania donovani, ldbpk_331470 |
|
69
|
281
|
4riyA |
Crystal structure of an egfr/her3 kinase domain heterodimer containing the cancer-associated her3-e909g mutation |
|
107
|
345
|
4qp7A |
Crystal structure of erk2 in complex with 2-(1h-pyrazol-4-yl)-5h-pyrrolo[2,3-b]pyrazine |
|
70
|
281
|
4riwA |
Crystal structure of an egfr/her3 kinase domain heterodimer |
|
88
|
323
|
4rj5A |
Egfr kinase (t790m/l858r) with inhibitor compound 5 |
|
110
|
345
|
4qp9A |
Crystal structure of erk2 in complex with 7-(1-propyl-1h-pyrazol-4-yl)-2-(pyridin-4-yl)-5h-pyrrolo[2,3-b]pyrazine |
|
82
|
278
|
4qyfA |
Chk1 kinase domain in complex with aminopyrazine compound 13 |
|
77
|
297
|
4rixB |
Crystal structure of an egfr/her3 kinase domain heterodimer containing the cancer-associated her3-q790r mutation |
|
123
|
358
|
4qtdA |
Structure of human jnk1 in complex with sch772984 and the amppnp-hydrolysed triphosphate revealing the second type-i binding mode |
|
79
|
273
|
4rc2A |
Crystal structure of ser/thr kinase pim1 in complex with mitoxantrone derivatives |
|
145
|
478
|
4qoxA |
Crystal structure of cdpk4 from plasmodium falciparum, pf3d7_0717500 |
|
100
|
326
|
4r7hA |
Crystal structure of fms kinase domain with a small molecular inhibitor, plx3397 |
|
88
|
308
|
4qqcA |
Crystal structure of fgf receptor (fgfr) 4 kinase domain in complex with fiin-2, an irreversible tyrosine kinase inhibitor capable of overcoming fgfr kinase gate-keeper mutations |
|
95
|
302
|
4r7iA |
Crystal structure of fms kinase domain with a small molecular inhibitor, gleevec |
|
157
|
490
|
4rgjA |
Apo crystal structure of cdpk4 from plasmodium falciparum, pf3d7_0717500 |
|
108
|
345
|
4qp4A |
Crystal structure of erk2 in complex with n-cyclohexyl-9h-purin-6-amine |
|
108
|
341
|
4qyyA |
Discovery of novel, dual mechanism erk inhibitors by affinity selection screening of an inactive kinase state |
|
97
|
285
|
4qmtA |
Mst3 in complex with hesperadin |
|
90
|
345
|
4qpmA |
Structure of bub1 kinase domain |
|
91
|
322
|
4rj4A |
Egfr kinase (t790m/l858r) with inhibitor compound 6 |
|
89
|
263
|
4rg0A |
Crystal structure of btk kinase domain complexed with 2-[8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(4-methylpiperazin-1-yl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-1-oxo-3,4-dihydroisoquinolin-6-yl]-2-methyl-propanenitrile |
|
95
|
334
|
4ra5A |
Human protein kinase c theta in complex with ligand compound 11a (6-[(1,3-dimethyl-azetidin-3-yl)-methyl-amino]-4(r)-methyl-7-phenyl-2,10-dihydro-9-oxa-1,2,4a-triaza-phenanthren-3-one) |
|
83
|
287
|
4qpsA |
Crystal structure of jak3 complexed to n-[3-(6-phenylamino-pyrazin-2-yl)-3h-benzoimidazol-5-yl]-acrylamide |
|
74
|
272
|
4r5yA |
The complex structure of braf v600e kinase domain with a novel braf inhibitor |
|
92
|
287
|
4qmuA |
Mst3 in complex with jnj-7706621, 4-({5-amino-1-[(2,6-difluorophenyl)carbonyl]-1h-1,2,4-triazol-3-yl}amino)benzenesulfonamide |
|
115
|
349
|
4r3cA |
Crystal structure of p38 alpha map kinase in complex with a novel isoform selective drug candidate |
|
96
|
287
|
4qmwA |
Mst3 in complex with pp-121, 1-cyclopentyl-3-(1h-pyrrolo[2,3-b]pyridin-5-yl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine |
|
80
|
278
|
4qyeA |
Chk1 kinase domain in complex with diarylpyrazine compound 1 |
|
53
|
168
|
4q5eA |
Shigella effector kinase ospg bound to e2-ub ubch7-ub conjugate |
|
71
|
297
|
4riwB |
Crystal structure of an egfr/her3 kinase domain heterodimer |
|
95
|
290
|
4qmpA |
Mst3 in complex with cdk1/2 inhibitor iii, 5-amino-3-{[4-(aminosulfonyl)phenyl]amino}-n-(2,6-difluorophenyl)-1h-1,2,4-triazole-1-carbothioamide |
|
87
|
299
|
4qqjA |
Crystal structure of fgf receptor (fgfr) 4 kinase domain harboring the v550l gate-keeper mutation |
|
84
|
335
|
4ra4A |
Crystal structure of human protein kinase c alpha in complex with compound 28 ((r)-6-((3s,4s)-1,3-dimethyl-piperidin-4-yl)-7-(2-fluoro-phenyl)-4-methyl-2,10-dihydro-9-oxa-1,2,4a-triaza-phenanthren-3-one) |
|
86
|
308
|
4r6vA |
Crystal structure of fgf receptor (fgfr) 4 kinase harboring the v550l gate-keeper mutation in complex with fiin-3, an irreversible tyrosine kinase inhibitor capable of overcoming fgfr kinase gate-keeper mutations |
|
86
|
289
|
4rqvA |
Crystal structure of pdk1 in complex with atp and the pif-pocket ligand rs2 |
|
105
|
349
|
4qp3A |
Crystal structure of erk2 in complex with (s)-2-((9h-purin-6-yl)amino)-3-phenylpropan-1-ol |
|
88
|
322
|
4r5sA |
Crystal structure of egfr 696-1022 l858r in complex with fiin-3 |
|
106
|
329
|
4rllA |
Crystal structure of human ck2alpha in complex with the atp-competitive inhibitor 4-[(e)-(fluoren-9-ylidenehydrazinylidene)-methyl] benzoate |
|
101
|
349
|
4qp6A |
Crystal structure of erk2 in complex with 5h-pyrrolo[2,3-b]pyrazine |
|
92
|
289
|
4qmoA |
Mst3 in complex with imidazolo-oxindole pkr inhibitor c16 |
|
111
|
349
|
4qtaA |
Structure of human erk2 in complex with sch772984 revealing a novel inhibitor-induced binding pocket |
|
76
|
273
|
4rc3A |
Crystal structure of ser/thr kinase pim1 in complex with mitoxantrone derivatives |
|
82
|
285
|
4r1yA |
Identification and optimization of pyridazinones as potent and selective c-met kinase inhibitor |
|
79
|
271
|
4qygA |
Chk1 kinase domain in complex with diazacarbazole compound 14 |
|
79
|
295
|
4rj3A |
Cdk2 with egfr inhibitor compound 8 |
|
97
|
289
|
4qmvA |
Mst3 in complex with pf-03814735, n-{2-[(1s,4r)-6-{[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-1,2,3,4-tetrahydro-1,4-epiminonaphthalen-9-yl]-2-oxoethyl}acetamide |
